Related Experiment Videos
Low-dose bromocriptine therapy in Parkinson's disease
Archives of Neurology
|June 1, 1985
Summary
Low-dose bromocriptine (20 mg daily or less) showed modest benefits for Parkinson's disease symptoms, particularly tremor. Optimal results were seen with 7.5-15 mg daily, suggesting it may aid carbidopa and levodopa treatment.
Area of Science:
- Neurology
- Pharmacology
Background:
- Parkinson's disease is a progressive neurodegenerative disorder.
- Current treatments like carbidopa and levodopa (Sinemet) manage symptoms but have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of low-dose bromocriptine mesylate in Parkinson's disease patients.
- To determine optimal dosage and potential benefits as an adjunct therapy.
Main Methods:
- A double-blind study was conducted over 40 weeks.
- Participants received daily bromocriptine doses of 20 mg or less.
- Efficacy and adverse effects were monitored.
Main Results:
- Nine of 16 participants completed the study.
- Bromocriptine therapy provided modest, significant improvements, especially in tremor.
- Peak efficacy occurred at 7.5-15 mg daily; efficacy decreased near 20 mg.
- Adverse effects were common but generally mild.
Conclusions:
- Low-dose bromocriptine may be a beneficial addition to carbidopa and levodopa therapy for Parkinson's disease.
- The drug demonstrated efficacy in improving motor symptoms, particularly tremor.
- Careful dose titration is recommended to maximize benefits and minimize side effects.